IO Biotech announced that the University of California Davis Comprehensive Cancer Center has dosed the first patient in its investigator-initiated trial which aims to evaluate IO102-IO103, the company’s investigational immune-modulating cancer vaccine, in combination with pembrolizumab in patients with BCG-unresponsive or intolerant, non-muscle invasive bladder cancer. “We are pleased to be supporting this trial with the University of California Davis Comprehensive Cancer Center,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. “We look forward to seeing the safety and efficacy results of this trial to further support the development of IO102-IO103 as the potential backbone of combination therapies for treating multiple types of cancer.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IOBT:
- IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center
- IO Biotech appoints Qasim Ahmad MD, CMO, Faulkner CTO
- IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer
- 2 “Strong Buy” Penny Stocks That Could Rally Over 300%
- IO Biotech announces achievement of Phase 3 trial recruitment milestone